Dai Chihara, M.D., Ph.D.

Peer-Reviewed Articles

1. Olszewski AJ, Ollila TA, Chihara D, Shouse G, Grover N, Karmali R, Torka P, Thomas C, Geethakumari PR, Barta SK, Bartlett NL, Epperla N. Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma. Haematologica, 2025. e-Pub 2025. PMID: 41307133.
2. Luo Z, Li M, Primeaux B, Shah R, Lin R, Iyer SP, Nastoupil LJ, Green MR, Westin JR, Flowers CR, Chihara D. Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019. Blood Adv, 2025. e-Pub 2025. PMID: 41201381.
3. Dai Y, Kizhakeyil A, Chihara D, Li X, Liu Y, Sainz Zuniga TP, Wilson A, Henderson J, Vibe D, Petrosyants A, Jacobson C, Sarachakov A, Nomie K, Kryukov K, Bagaev A, Chauhan A, Westin JR, Flowers CR, Vega F, Wang L, Green MR. Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma. Nat Genet 57(11):2715-2727, 2025. e-Pub 2025. PMID: 41120574.
4. Strati P, Feng L, Tyshevich A, Shavronskaya D, Alesse J, English N, Sheehan E, Syzrantsev N, Nesmelov A, Zhuang TZ, Chihara D, Westin JR, Ahmed S, Fayad LE, Henderson J, Dent K, McChesney E, Neelapu SS, Flowers CR. A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma. Clin Cancer Res 31(19):4079-4088, 2025. e-Pub 2025. PMID: 40729376.
5. Akkad N, Feng L, Westin JR, Hagemeister FB, Lee HJ, Fayad L, Ahmed S, Nair R, Rodriguez MA, Strati P, Chihara D, Flowers CR, Claret L, Ibanez K, Wang M, Fowler NH, Henderson J, Davis RE, Neelapu SS, Green M, Nastoupil LJ. A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma. Blood Adv 9(17):4396-4404, 2025. e-Pub 2025. PMID: 40517417.
6. Mondello P, Negaard B, Feldman AL, Link BK, Casulo C, Chihara D, Russler-Germain D, Romancik J, Gribbin C, Haddadi S, Mou E, Micallef IN, Johnston PB, Novak J, Wang Y, King RL, Novak AJ, Habermann TM, Martin P, Kahl B, Nowakowski GS, Nastoupil LJ, Cerhan JR, Flowers CR, Lossos IS, Burack RW, Maurer MJ, Ansell SM. Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts. Blood Cancer J 15(1):134, 2025. e-Pub 2025. PMID: 40781119.
7. Strati P, Feng L, Westin JR, Nair R, Fayad LE, Rodriguez MA, Chihara D, Malpica L, Henderson J, Gallardo M, Rivera M, Wang I, Bolshakova A, Radko A, Kurtz D, Alig SK, Flowers CR, Alizadeh AA, Neelapu SS. Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial. Nat Commun 16(1):7300, 2025. e-Pub 2025. PMID: 40775236.
8. Li X, Singhal K, Deng Q, Chihara D, Russler-Germain D, Harkins RA, Henderson J, Arita K, Kizhakeyil A, Sun R, Lakra P, Hussein U, Foltz JA, Wilson A, Schmidt E, Nizamuddin I, Dinh T, Kesaraju A, Hamilton MP, Allen C, Gandhi MK, Tobin J, Jiang A, Hilton L, Scott DW, Vega F, Flowers CR, Westin JR, Griffith OL, Fehniger TA, Griffith M, Green MR. Large B cell lymphoma microenvironment archetype profiles. Cancer Cell 43(7):1347-1364.e13, 2025. e-Pub 2025. PMID: 40920660.
9. Chihara D, Steiner RE, Nair R, Feng L, Ahmed S, Strati P, Malpica L, Griffith DP, Mathew SA, Montinez W, Masand G, Samaniego F, Rodriguez MA, Hagemeister FB, Fayad LE, Iyer SP, Nastoupil LJ, Neelapu SS, Flowers CR, Westin JR. Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas. Blood Adv 9(7):1485-1491, 2025. e-Pub 2025. PMID: 39908461.
10. Long JP, Prakash R, Edelkamp P Jr, Knafl M, Lionel AC, Nair R, Ahmed S, Strati P, Castillo LEM, Al-Zaki A, Chien K, Chihara D, Westin J, Khawaja F, Nastoupil LJ, Mulanovich V, Futreal A, Woodman SE, Daver NG, Flowers CR, Neelapu S, Manzano JG, Iyer SP. Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy. JAMA Netw Open 8(4):e253455, 2025. e-Pub 2025. PMID: 40193078.
11. Yamshon S, Koff JL, Larson MC, Kahl BS, Casulo C, Lossos IS, Haddadi S, Stanchina M, Chihara D, Ayers A, Habermann TM, Wang Y, Khurana A, Nowakowski GS, Reicks TW, Farooq U, Link BK, Cohen JB, Martin P, Li J, Shewade A, Batlevi CL, Lo-Rossi A, Fox D, Masaquel A, Mun Y, Cerhan JR, Flowers CR, Maurer MJ, Nastoupil LJ. Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study. Am J Hematol 100(4):606-615, 2025. e-Pub 2025. PMID: 39918101.
12. Manzar GS, Wu SY, Dudzinski SO, Cha EE, Yoder AK, Corrigan KL, Nasr LF, Sallard G, Ahmed S, Fayad LE, Chihara D, Nair R, Westin JR, Daher M, Neelapu SS, Nastoupil LJ, Gunther JR, Pinnix CC, Dabaja BS, Strati P, Fang PQ. Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell Therapy. Int J Radiat Oncol Biol Phys 121(4):1011-1025, 2025. e-Pub 2025. PMID: 39303997.
13. Day JR, Larson MC, Durani U, Koff JL, Wang Y, Habermann TM, Lossos IS, Nastoupil LJ, Strouse C, Chihara D, Martin P, Leonard JP, Cohen JB, Kahl BS, Ruan J, Burack WR, Friedberg JW, Cerhan JR, Flowers CR, Link BK, Maurer MJ, Casulo C. Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium. Blood Adv 9(5):1013-1023, 2025. e-Pub 2025. PMID: 39602301.
14. Prasad R, Rehman A, Rehman L, Darbaniyan F, Blumenberg V, Schubert ML, Mor U, Zamir E, Schmidt S, Hayase T, Chang CC, McDaniel L, Flores I, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Wang M, Jain P, Nastoupil LJ, Westin J, Arora R, Turner J, Khawaja F, Wu R, Dennison JB, Menges M, Hidalgo-Vargas M, Reid K, Davila ML, Dreger P, Korell F, Schmitt A, Tanner MR, Champlin RE, Flowers CR, Shpall EJ, Hanash S, Neelapu SS, Schmitt M, Subklewe M, Francois-Fahrmann J, Stein-Thoeringer CK, Elinav E, Jain MD, Hayase E, Jenq RR, Saini NY. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood 145(8):823-839, 2025. e-Pub 2025. PMID: 39441941.
15. Florindez JA, Chihara D, Reis IM, Lossos IS, Alderuccio JP. Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population-based analysis. Blood Adv 8(16):4423-4432, 2024. e-Pub 2024. PMID: 38954843.
16. Maurer MJ, Casulo C, Larson MC, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan JR, Link BK, Flowers CR. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma. Haematologica 109(7):2177-2185, 2024. e-Pub 2024. PMID: 38031804.
17. Gunther JR, Xu J, Bhutani MS, Strati P, Fang PQ, Wu SY, Dabaja BS, Dong W, Bhosale PR, Flowers CR, Nair R, Malpica Castillo L, Fayad L, Iyer SP, Parmer S, Wang M, Lee HJ, Samaniego F, Westin J, Ahmed S, Nze CC, Jain P, Neelapu SS, Rodriguez MA, Chihara D, Nastoupil LJ, Pinnix CC. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial. Lancet Haematol 11(7):e521-e529, 2024. e-Pub 2024. PMID: 38843856.
18. Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, Burack WR, McDonnell TJ, Vega F, Chapman JR, Syrbu S, Vij KR, Inghirami G, Leonard JP, Bernal-Mizrachi L, Farooq U, Witzig TE, Weiner GJ, Wang Y, Alderuccio JP, Slager SL, Larson MC, Riska SM, Gysbers BJ, Lunde JJ, Reicks TW, Ayers AA, O'Leary CB, Yost KJ, Liu H, Nowakowski GS, Ruan J, Chihara D, Koff JL, Casulo C, Thompson CA, Cohen JB, Kahl BS, Nastoupil LJ, Lossos IS, Friedberg JW, Martin P, Flowers CR. The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. Am J Hematol 99(3):408-421, 2024. e-Pub 2024. PMID: 38217361.
19. Manzar GS, Cha EE, Corrigan KL, Yoder AK, Schrank BR, Nasr LF, Chihara D, Castillo LM, Nair R, Jain P, Neelapu SS, Rodriguez MA, Strati P, Nastoupil LJ, Gunther JR, Dabaja BS, Pinnix CC, Wu SY, Fang PQ. Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs. Front Oncol 14:1447020, 2024. e-Pub 2024. PMID: 39324011.
20. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer SP, Horowitz S, Nastoupil LJ, Nair R, Hassan A, Daoud TE, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv 7(21):6785-6789, 2023. e-Pub 2023. PMID: 37389847.
21. Chien KS, Peterson CB, Young E, Chihara D, Manasanch EE, Ramdial JL, Thompson PA. Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies. Blood Adv 7(19):5691-5697, 2023. e-Pub 2023. PMID: 36696472.
22. Chihara D, Liao L, Tkacz J, Franco A, Lewing B, Kilgore KM, Nastoupil LJ, Chen L. Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma. Blood 142(12):1047-1055, 2023. e-Pub 2023. PMID: 37339585.
23. Alderuccio JP, Reis IM, Koff JL, Larson MC, Chihara D, Zhao W, Haddadi S, Habermann TM, Martin P, Chapman JR, Strouse C, Kahl BS, Cohen JB, Friedberg JW, Cerhan JR, Flowers CR, Lossos IS. Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma. Blood 141(15):1888-1893, 2023. e-Pub 2023. PMID: 36735908.
24. Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Muller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
25. Chihara D, Lin R, Flowers CR, Finnigan SR, Cordes LM, Fukuda Y, Huang EP, Rubinstein LV, Nastoupil LJ, Ivy SP, Doroshow JH, Takebe N. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet 400(10351):512-521, 2022. e-Pub 2022. PMID: 35964611.
26. Chihara D, Huang EP, Finnigan SR, Cordes LM, Skorupan N, Fukuda Y, Rubinstein LV, Ivy SP, Doroshow JH, Nastoupil LJ, Flowers CR, Takebe N. Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. J Clin Oncol 40(17):1949-1957, 2022. e-Pub 2022. PMID: 35263120.
27. Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan J, Flowers CR, Link BK, Maurer MJ. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol 9(4):e289-e300, 2022. e-Pub 2022. PMID: 35358443.
28. Chihara D, Arons E, Stetler-Stevenson M, Yuan C, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James-Echenique L, Tai CH, Patel KP, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv 5(23):4807-4816, 2021. e-Pub 2021. PMID: 34607348.
29. Chihara D, Dores GM, Flowers CR, Morton LM. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood 138(9):785-789, 2021. e-Pub 2021. PMID: 33822002.
30. Rogers KA, Andritsos LA, Wei L, McLaughlin EM, Ruppert AS, Anghelina M, Blachly JS, Call T, Chihara D, Dauki A, Guo L, Ivy SP, James LR, Jones D, Kreitman RJ, Lozanski G, Lucas DM, Ngankeu A, Phelps M, Ravandi F, Schiffer CA, Carson WE, Jones JA, Grever MR. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood 137(25):3473-3483, 2021. e-Pub 2021. PMID: 33754642.
31. Pang Y, Chihara D. Primary and secondary central nervous system mature T- and NK-cell lymphomas. Semin Hematol 58(2):123-129, 2021. e-Pub 2021. PMID: 33906722.
32. Fujimoto A, Ishida F, Izutsu K, Yamasaki S, Chihara D, Suzumiya J, Mitsui T, Doki N, Sakai H, Kobayashi H, Kanda J, Fukuda T, Atsuta Y, Suzuki R. Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. Bone Marrow Transplant 56(2):347-356, 2021. e-Pub 2021. PMID: 32778688.
33. Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. J Clin Oncol 38(14):1527-1538, 2020. e-Pub 2020. PMID: 32109194.
34. Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J 10(5):48, 2020. e-Pub 2020. PMID: 32366841.
35. Kondo E, Ikeda T, Izutsu K, Chihara D, Shimizu-Koresawa R, Fujii N, Sakai T, Kondo T, Kubo K, Kato Y, Akasaka T, Fukuda T, Ichinohe T, Atsuta Y, Suzumiya J, Suzuki R. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry. Biol Blood Marrow Transplant 25(5):899-905, 2019. e-Pub 2019. PMID: 30664936.
36. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol 185(2):334-338, 2019. e-Pub 2019. PMID: 29978452.
37. Chihara D, Wong S, Feldman T, Fanale MA, Sanchez L, Connors JM, Savage KJ, Oki Y. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin. Hematol Oncol 37(1):35-38, 2019. e-Pub 2019. PMID: 30209819.
38. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750-758, 2017. e-Pub 2017. PMID: 27983760.
39. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122(20):3145-3151, 2016. e-Pub 2016. PMID: 27351173.
40. Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer 122(18):2857-66, 2016. e-Pub 2016. PMID: 27244347.
41. Cheah CY, Brockelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. Am J Hematol 91(9):894-9, 2016. e-Pub 2016. PMID: 27222367.
42. Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 174(5):760-6, 2016. e-Pub 2016. PMID: 27301277.
43. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol 2(8):1065-9, 2016. e-Pub 2016. PMID: 27227654.
44. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 27(7):1317-23, 2016. e-Pub 2016. PMID: 27091808.
45. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27(5):895-901, 2016. e-Pub 2016. PMID: 26802151.
46. Cheah CY, Milgrom S, Chihara D, Gombos DS, Pinnix CC, Dabaja BS, Fowler NH. Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. Neuro Oncol 18(4):575-81, 2016. e-Pub 2016. PMID: 26487691.
47. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172(1):80-8, 2016. e-Pub 2016. PMID: 26648336.
48. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 2015. e-Pub 2015. PMID: 26260306.
49. Chihara D, Ito H, Izutsu K, Hattori M, Nishino Y, Ioka A, Matsuda T, Ito Y. Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006. Int J Cancer 137(5):1217-23, 2015. e-Pub 2015. PMID: 25694231.
50. Chihara D, Asano N, Ohmachi K, Kinoshita T, Okamoto M, Maeda Y, Mizuno I, Matsue K, Uchida T, Nagai H, Nishikori M, Nakamura S, Ogura M, Suzuki R. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan. Br J Haematol 170(5):657-68, 2015. e-Pub 2015. PMID: 25953436.
51. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 26(6):1175-1179, 2015. e-Pub 2015. PMID: 25712454.
52. Chihara D, Asano N, Ohmachi K, Nishikori M, Okamoto M, Sawa M, Sakai R, Okoshi Y, Tsukamoto N, Yakushijin Y, Nakamura S, Kinoshita T, Ogura M, Suzuki R. Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). Ann Oncol 26(5):966-973, 2015. e-Pub 2015. PMID: 25712457.
53. Chihara D, Romer AI, Bentzinger CF, Rudnicki MA, Krauss RS. PAX7 is required for patterning the esophageal musculature. Skelet Muscle 5:39, 2015. e-Pub 2015. PMID: 26635949.
54. Ito Y, Miyashiro I, Ito H, Hosono S, Chihara D, Nakata-Yamada K, Nakayama M, Matsuzaka M, Hattori M, Sugiyama H, Oze I, Tanaka R, Nomura E, Nishino Y, Matsuda T, Ioka A, Tsukuma H, Nakayama T. Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci 105(11):1480-6, 2014. e-Pub 2014. PMID: 25183551.
55. Ueda N, Chihara D, Kohno A, Tatekawa S, Ozeki K, Watamoto K, Morishita Y. Predictive value of circulating angiopoietin-2 for endothelial damage-related complications in allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 20(9):1335-40, 2014. e-Pub 2014. PMID: 24796281.
56. Sugihara H, Chihara D, Seike K, Fukumoto K, Fujisawaa M, Suehara Y, Nishida Y, Takeuchi M, Matsue K. Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment. Blood Cancer J 4(8):e235, 2014. e-Pub 2014. PMID: 25083819.
57. Tajika M, Matsuo K, Ito H, Chihara D, Bhatia V, Kondo S, Tanaka T, Mizuno N, Hara K, Hijioka S, Imaoka H, Matsumoto K, Nakamura T, Yatabe Y, Yamao K, Niwa Y. Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT). J Gastroenterol 49(5):843-52, 2014. e-Pub 2014. PMID: 23793380.
58. Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, Kaneko H, Kato K, Hasegawa Y, Chou T, Sugahara H, Henzan H, Sakamaki H, Suzuki R, Suzumiya J. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant 20(5):684-9, 2014. e-Pub 2014. PMID: 24492141.
59. Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, Tomotaka S, Morton LM, Weisenburger DD, Matsuo K. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164(4):536-45, 2014. e-Pub 2014. PMID: 24245986.
60. Chihara D, Ito H, Matsuda T, Katanoda K, Shibata A, Taniguchi S, Utsunomiya A, Sobue T, Matsuo K. Association between decreasing trend in the mortality of adult T-cell leukemia/lymphoma and allogeneic hematopoietic stem cell transplants in Japan: analysis of Japanese vital statistics and Japan Society for Hematopoietic Cell Transplantation (JSHCT). Blood Cancer J 3(11):e159, 2013. e-Pub 2013. PMID: 24241399.
61. Chihara D, Ito H, Katanoda K, Shibata A, Matsuda T, Tajima K, Sobue T, Matsuo K. Increase in incidence of adult T-cell leukemia/lymphoma in non-endemic areas of Japan and the United States. Cancer Sci 103(10):1857-60, 2012. e-Pub 2012. PMID: 22738276.
62. Chihara D, Nance J. An E-cadherin-mediated hitchhiking mechanism for C. elegans germ cell internalization during gastrulation. Development 139(14):2547-56, 2012. e-Pub 2012. PMID: 22675206.
63. Chihara D, Matsuo K, Kanda J, Hosono S, Ito H, Nakamura S, Seto M, Morishima Y, Tajima K, Tanaka H. Inverse association between soy intake and non-Hodgkin lymphoma risk among women: a case-control study in Japan. Ann Oncol 23(4):1061-6, 2012. e-Pub 2012. PMID: 21765045.
64. Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, Tanimoto M, Iwasaki T, Isoda A, Sakai A, Kobayashi H, Kitamura K, Matsue K, Taniwaki M, Tamashima S, Saburi Y, Masunari T, Naoe T, Nakamura S, Kinoshita T. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood 119(12):2837-43, 2012. e-Pub 2012. PMID: 22308294.
65. Chihara D, Ito H, Matsuda T, Katanoda K, Shibata A, Saika K, Sobue T, Matsuo K. Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S. Oncologist 17(12):1547-50, 2012. e-Pub 2012. PMID: 22971523.
66. Kato H, Kagami Y, Kodaira T, Oka S, Oki Y, Chihara D, Taji H, Yatabe Y, Nakamura T, Nakamura S, Seto M, Yamamoto K, Morishima Y. Nodal relapse after Helicobacter pylori eradication in a patient with primary localized gastric mucosa-associated lymphoid tissue lymphoma. Am J Gastroenterol 106(3):549-51, 2011. e-Pub 2011. PMID: 21378774.
67. Speca DJ, Chihara D, Ashique AM, Bowers MS, Pierce-Shimomura JT, Lee J, Rabbee N, Speed TP, Gularte RJ, Chitwood J, Medrano JF, Liao M, Sonner JM, Eger EI 2nd, Peterson AS, McIntire SL. Conserved role of unc-79 in ethanol responses in lightweight mutant mice. PLoS Genet 6(8), 2010. e-Pub 2010. PMID: 20714347.

Review Articles

1. Akkad N, Chihara D. License for a CAR T: Examining patient eligibility. Semin Hematol 61(5):284-289, 2024. e-Pub 2024. PMID: 39117489.
2. Chihara D, Nastoupil LJ, Flowers CR. Clinical approaches for integrating machine learning for patients with lymphoma: Current strategies and future perspectives. Br J Haematol 202(2):219-229, 2023. e-Pub 2023. PMID: 37170487.
3. Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, Chihara D, Dearden C, Demeter J, Dietrich S, Else M, Epperla N, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Jorgensen J, Juliusson G, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Thompson PA, Troussard X, Zent CS, Zenz T, Zinzani PL, Wormann B, Rai K, Grever M. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J 12(12):165, 2022. e-Pub 2022. PMID: 36509740.
4. Chihara D, Miljkovic M, Iyer SP, Vega F. Targeted based therapy in nodal T-cell lymphomas. Leukemia 35(4):956-967, 2021. e-Pub 2021. PMID: 33664464.
5. Chihara D, Oki Y. Central Nervous System Involvement in Peripheral T Cell Lymphoma. Curr Hematol Malig Rep 13(1):1-6, 2018. e-Pub 2018. PMID: 29374824.
6. Krauss RS, Chihara D, Romer AI. Embracing change: striated-for-smooth muscle replacement in esophagus development. Skelet Muscle 6:27, 2016. e-Pub 2016. PMID: 27504178.
7. Koff JL, Chihara D, Phan A, Nastoupil LJ, Williams JN, Flowers CR. To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes. Curr Hematol Malig Rep 10(3):244-55, 2015. e-Pub 2015. PMID: 26104907.
8. Utsunomiya A, Choi I, Chihara D, Seto M. Recent advances in the treatment of adult T-cell leukemia-lymphomas. Cancer Sci 106(4):344-51, 2015. e-Pub 2015. PMID: 25613789.
9. Yoshida N, Chihara D. Incidence of adult T-cell leukemia/lymphoma in nonendemic areas. Curr Treat Options Oncol 16(2):7, 2015. e-Pub 2015. PMID: 25762122.
10. Chihara D, Oki Y. Brentuximab vedotin for treatment of systemic T-cell lymphoma. Expert Opin Biol Ther 14(10):1519-26, 2014. e-Pub 2014. PMID: 25200691.

Other Articles

1. Bommier C, Link BK, Gysbers BJ, Maurer MJ, Larson MC, Khurana A, Wang Y, Thompson CA, Chihara D, Alderuccio JP, Koff JL, Epperla N, Conconi A, Lossos IS, Nowakowski GS, Feldman AL, Habermann TM, King RL, Cerhan JR Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature. Blood Adv 8(23):5939-5948, 2024. PMID: 39321424.
2. Nakao M, Chihara D, Niimi A, Ueda R, Tanaka H, Morishima Y, Matsuo K Impact of being overweight on outcomes of hematopoietic SCT: a meta-analysis. Bone Marrow Transplant 49(1):66-72, 2014. PMID: 23955636.

Editorials

1. Chihara D. Synthetic lethality in ATL. Blood 141(10):1096-1098, 2023. PMID: 36893010.

Abstracts

1. Li X, Singhal K, Deng Q, Chihara D, Russler-Germain DA, Hussein U, Foltz JA, Henderson J, Wilson A, Schmid E, Nizamuddin IA, Dinh T, Sun R, Kesaraju A, Hilton LK, Scott DW, Vega F, Flower CR, Griffith O, Fehnige TA, Griffith M, Green MR. Comprehensive Characterization and Validation of the Tumor Microenvironment in Patients with Relapsed/Refractory Large B-Cell Lymphoma Identifies Subgroups with Greatest Benefit from CD19 CAR T-Cell Therapy. American Society of Hematology, 2024. e-Pub 2024.
2. Elias A, Prakash R, Nair R, Malpica L, Lee HJ, Maples E, Carlson S, Fayad LE, Patel KK, Ahmed S, Iyer SP. Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data. American Society of Hematology - ASH, 2024. e-Pub 2024.
3. Toumeh N, Larson MC, Negaard BJ, Casulo C, Ahmed S, Maurer MJ, Feldman AL, Link BK, Cohen JB, Habermann TM, Chihara D, Lossos IS, Friedberg JW, Kahl B, Martin P, Flowers CR, Cerhan JR, Williams AM, Rosenthal AC, Thompson CA, Durani U. Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study. American Society of Hematology (Blood), 2024. e-Pub 2024.
4. Lionel A, Kui N, Sun R, Aboismail E, Tewari SO, Zaki AA, Gouni S, Jain P, Chihara D, Iyer SP, Wang M, Nair R, Malpica Castillo LE, Lee HJ, Nze C, Fayad LE, Hagemeister F, Rodriguez MA, Ayers AA, Gutierrez C, Rondon G, Khawaja F, Kebriaei P, Shpall EJ, Flowers CR, Westin JR, Strati P, Wang W, Wang SA, Ahmed S, Neelapu SS. Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma. American Society of Hematology (Blood), 2024. e-Pub 2024.
5. Yamshon S, Koff JL, Larson MC, Kahl BS, Casulo C, Lossos IS, Haddadi S, Stanchina MD, Chihara D, Ayers AA, Habermann TM, Wang Y, Khurana A, Nowakowski GS, Reicks TW, Farooq U, Link BK, Cohen JB, Martin P, Li J, Shewade A, Batlevi CL, Lo-Rossi A, Fox D, Masaquel A, Mun Y, Cerhan JR, Flowers CR, Maurer MJ, Nastoupil L. Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study. American Society of Hematology (Blood), 2024. e-Pub 2024.
6. Gouni S, Lionel A, Feng L, Gaulin C, Reddy T, Gonugunta AS, Chu V, Hopper T, Ayers AA, Jackson I, Zaki AA, Hildebrandt MA, Nastoupil L, Chihara D, Nze C, Ramdial J, Shpall EJ, Westin JR, Flowers CR, Strati P, Neelapu SS, Lynn R, Ahmed S. Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma. American Society of Hematology (Blood), 2024. e-Pub 2024.
7. Kim K, Chihara D, Fayad LE, Neelapu SS, Ahmed S, Hagemeister F, Nze C, Iyer SP, Jain P, Wang M, Strati P, Furqan F, Chauhan A, R Green MR, Flowers CR, Westin JR. Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma. American Society of Hematology (Blood), 2024. e-Pub 2024.
8. Kim K, Ayers A, Ahmed S, Claret L, Strati P, Nair R, Nze C, Ramdial J, Torres J, Shpall EJ, Fayad LE, Nastoupil L, Westin JR, Flowers CR, Neelapu SS, Chihara D. Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma. American Society of Hematology (Blood), 2024. e-Pub 2024.
9. Tsang M, Noble BN, Casulo C, Thompson CA, Rosenthal AC, Chihara D, Mou E, Durani U, Williams AM, Hildebrandt MA, Yost KJ, Larson MC, Gysbers B, Maurer MJ, Feldman AL, Jaye DL, Tilburt J, Major A, Hilal T, Wang Y, Koehler A, Call TG, Parikh SA, Munoz JL, Thanarajasingam G, Nastoupil L, Nowakowski GS, Cohen JB, Habermann TM, Strouse C, Lossos IS, Kahl BS, Martin P, Flowers CR, Cerhan JR, Dueck AC. Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study. American Society of Hematology (Blood), 2024. e-Pub 2024.
10. Zhuang OZ, Feng L, Chihara D, Nze C, Ayers AA, Noorani M, Ayres JD, Duenas DE, Balakrishnan K, Nesterenko E, Meerson M, Zornikova K, Nomie K, Kotlov N, Fowler N, Rodriguez MA, Neelapu SS, Flowers CR, Strati P. Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma. American Society of Hematology (Blood), 2024. e-Pub 2024.
11. Kim K, Ayers A, Ahmed S, Claret L, Strati P, Nair R, Nze C, Ramdial J, Torres J, Shpall EJ, Fayad LE, Nastoupil L, Westin JR, Flowers CR, Neelapu SS, Chihara D. Utility of PET/CT Imaging in Predicting Outcomes of Patients with Lymphoid Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis from a Single Tertiary Center. American Society of Hematology, 2024. e-Pub 2024.
12. Saul EE, Valcarcel B, Ayers AA, Noorani M, Chihara D, Furqan F, Ahmed S, Iyer SP, Neelapu SS, Fayad LE, Hagemeister F, Nze C, Jain P, Wang M, Strati P, Chauhan A, Vega F, Flowers CR, Westin JR. Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma. American Society of Hematology (Blood), 2024. e-Pub 2024.
13. Chihara D, Balakrishnan K, MPhil, Masand G, Harkins RA, Akkad N, Novokreshchenova A, Bagaev A, Kotlov N, Postovalova E, Shugaev-Mendosa E, Gracheva Y, Lauziere K, Kaneunyenye L, McKenna B, Berlinski A, Walsh M, Larson L, Kotsinyan M, Samokhina A, Yong ST, Nomie K, Fowler NH, Flowers CR, Westin JR. Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma. American Society of Hematology (Blood), 2024. e-Pub 2024.
14. Steiner R, Bock AM, Herrera AF, Zulfa O, Hoffmann M, Ibrahimi S, Galanina N, Lee HJ, Green M, Lin R, Pinnix CC, Moskowitz A, Yahalom J, Chihara D. CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab. American Society of Hematology (Blood), 2024. e-Pub 2024.
15. Lionel A, Murphy K, Ayers AA, Flowers CR, Patel KP, DiNardo CD, Vega F, Chihara D. Survival Outcomes and Genetic Assessment in Patients with Dual Diagnoses of B-Cell and T-Cell Lymphomas. American Society of Hematology (Blood), 2024. e-Pub 2024.
16. Chihara D, Kane MJ, Flowers CR, Hobbs BP. Utilizing Synthetic Individual Patient Level Cohorts from Machine Learning on Clinical Trials to Define Endpoints for Bispecific Trials in Large B-Cell Lymphoma, 2024. e-Pub 2024.
17. Akkad N, Ayers A, Balakrishnan K, MPhil, Nastoupil L, Chihara D, Malpica L, Strati P, Li Z, Flowers CR. Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy. American Society of Hematology (Blood), 2024. e-Pub 2024.
18. Mondello P, Negaard BJ, Arcaini L, Tobin J, Chartier L, Link BK, Feldman AL, Chihara D, Casulo C, Cottereau AS, Guerra L, Olson J, Romancik JT, Haddadi S, Black H, Trevis T, Mou E, Tong TH, Moalem K, Johnston AM, Hampel PJ, Johnson J, Elizabeth S, Yang P, Kosciejew S, Elizabeth G, Manos K, Cheah CY, Salvaris R, Habermann TM, Martin P, Kahl BS, Nowakowski GS, Hodges G, Nastoupil L, Talaulikar D, Trotman J, Cerhan JR, Flowers CR, Lossos IS, Burack R, Luminari S, Morschhauser F, Ansell SM, Maurer MJ. Frontline R-CHOP and BR Have Similar Outcomes By SUVmax in Follicular Lymphoma. American Society of Hematology (Blood), 2024. e-Pub 2024.
19. Mondello P, Negaard BJ, Feldman AL, Link BK, Casulo C, Chihara D, Russler-Germain DA, Romancik J, Gribbin C, Haddadi S, Mou E, Micallef IN, Johnston PB, Novak AJ, Wang Y, King RL, Habermann TM, Martin P, Nowakowski GS, Nastoupil L, Cerhan JR, Flowers CR, Lossos IS, Burack R, Maurer MJ, Ansell SM. Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts. American Society of Hematology, 2024. e-Pub 2024.
20. Casulo C, Larson MC, Day JR, Durani U, Tsang M, Friedberg JW, Nowakowski GS, Koff JL, Chihara D, Burack R, Habermann TM, Nastoupil L, Lossos IS, Martin P, Holets M, Kahl BS, Cohen JJ, Cerhan JR, Flowers CR, Link BK, Maurer MJ. Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma. American Society of Hematology (Blood), 2024. e-Pub 2024.
21. Harkins RA, Chihara D, Flowers CR. Collective Analysis of Genomic Data Sets to Assess the Impact of Eligibility Criteria on Molecular Subsets in First-Line Clinical Trials for Patients with Diffuse Large B-Cell Lymphoma. American Society of Hematology (Blood), 2024. e-Pub 2024.
22. Florindez JA, Chihara D, Reis IM, Lossos, IS JAlderuccio JP. Risk of Transformation By Frontline Management in Follicular Lymphoma and Marginal Zone Lymphoma: A US Population-Based Analysis. American Society of Hematology (Blood) 142(Suppl 1), 2023. e-Pub 2023.
23. Tsang M, Noble BN, Bommier C, Casulo C, Thompson C, Rosenthal AC, Chihara D, Mou E, Durani U, Williams AM, Hildebrandt M, Yost K, Larson MC, Gysbers B, Maurer MJ, Slager SL, Feldman AL, Jaye DL, Tilburt J, Villasboas JCC, Major A, Pophali PA, Hilal T, Wang Y, Call TG, Koehler A, Munoz JL, Thanarajasingam G, Hampel PJ, Parikh SA, Nastoupil LJ, Witzig TE, Nowakowski GS, Ansell SM, Cohen JB, Habermann TM, Strouse C, Lossos IS, Kahl BS, Martin P, Flowers CR, Cerhan JR, Dueck AC. Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study. American Society of Hematology (Blood) 142(Suppl 1), 2023. e-Pub 2023.
24. Nastoupil LJ, Andersen CR, Ayers A, Wang Y, Habermann TM, Chihara D, Kahl BS, Link BK, Cohen JB, Martin P, Lossos IS, Casulo C, Lin R, Li Z, Larson MC, Maurer MJ, Huynh L, Gao C, Ramasubramanian R, Duh MS, Mutebi A, Wang T, Jun M, Wang A, Kamalakar R, Kalsekar A, Cerhan JR, Flowers CR. Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL). American Society of Hematology (Blood) 142(Suppl 1), 2023. e-Pub 2023.
25. Koff JL, Larson MC, Martin P, Cohen JB, Ayyappan SR, Link BK, Habermann TM, Wang Y, Khurana A, Nowakowski GS, Chihara D, Haddadi CS, Lossos IS, Casulo C, Kahl BS, Ayers A, Reicks TW, Flowers CR, Cerhan JR, Maurer MJ, Nastoupil LJ. LEO Consortium for Real World Evidence (CReWE): Outcomes after Second-Line Therapy in Large B-Cell Lymphoma By Treatment Era. American Society of Hematology (Blood) 142(Suppl 1), 2023. e-Pub 2023.
26. Gunther J, Xu J, Bhutani MS, Strati P, Fang P, Wu S, Dabaja BS, Dong W, Bhosale P, Flowers CR, Nair R, Malpica L, Jain P, Neelapu SS, Rodriguez MA, Chihara D, Nastoupil LJ, Pinnix CC. Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Gastric MALT Lymphoma. American Society of Hematology (Blood) 142(Suppl 2), 2023. e-Pub 2023.
27. Casulo C, Larson MC, Flowers CR, Habermann TM, Witzig TE, Wang Y, Nowakowski GS, Feldman AL, Nastoupil LJ, Chihara D, Burack R, Day JR, Durani U, Martin P, Cohen JB, Friedberg JW, Lossos IS, Kahl BS, Link BK, Cerhan JR, Maurer MJ. The FLIPI24 Prognostic Model Identifies Poor Outcomes in Non-Immunochemotherapy Treated Patients with Follicular Lymphoma. American Society of Hematology (Blood) 142(142):Suppl 1, 2023. e-Pub 2023.
28. Strati P, Feng L, Westin J, Nair R, Fayad L, Rodriguez MA, Chihara D, Malpica L, Henderson J, Gallardo M, Marques-Piubelli ML, Turova P, Zaitsev A, Wang I, Flowers CR, Nastoupil LJ, Neelapu SS. Addition of Acalabrutinib to Lenalidomide and Rituximab Induces High Complete Response Rates in Patients with Previously Untreated Follicular Lymphoma: Results of a Phase II Study. American Society of Hematology (Blood) 142(Suppl 1), 2023. e-Pub 2023.
29. Alderuccio JP, Stanchina MD, Koff JL, Reis IM, Saul EE, Larson MC, Chihara D, Zhao W, Habermann TM, Martin P, Nastoupil LJ, Chapman-Fredricks JR, Feldman AL, Link BK, Kahl BS, Cohen JB, Polar MK, Sassi RH, Moskowitz CH, Friedberg JW, Cerhan JR, Kuker R, Flowers CR, Lossos IS. PET/CT Enables Appropriate Staging in Extranodal Marginal Zone Lymphoma. American Society of Hematology 142(Suppl 1), 2023. e-Pub 2023.
30. Bommier C, Tsang M, Noble BN, Thompson C, Casulo C, Hildebrandt M, Rosenthal AC, Mou E, Durani U, Williams AM, Yost K, Larson MC, Gysbers B, Maurer MJ, Feldman AL, Jaye DL, Martin P, Cohen JB, Chihara D, Lossos IS, Strouse C, Kahl BS, Habermann TM, Flowers CR, Dueck AC, Cerhan JR. Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort. American Society of Hematology (Blood) 142(Suppl 1), 2023. e-Pub 2023.
31. Nair R, Ogundipe I, Gunther J, Medeiros LJ, Jain P, Nastoupil LJ, Pinnix CC, Malpica L, Ahmed S, Miranda R, Fayad L, Steiner RE, Hagemeister F, Lee, HJ Rodriguez MA, Strati P, Chihara D, Wang M, Nieto Y, Ramdial J, Al Zaki A, Nze C, Green MR, Dabaja BS, Xu J, Thakral B, Neelapu SS, Vega F, Flowers CR, Fang P, Westin J, Feng L, Iyer SP. Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience. American Society of Hematology (Blood) 142(Suppl 1), 2023. e-Pub 2023.
32. Maurer MJ, Khurana A, Farooq U, Romancik JT, Friedberg JW, Lossos IS, Kahl BS, Martin P, Chihara D, Feldman AL, Syrbu S, Jaye DL, Cahn E, Habermann TM, Link BK, Cerhan JR, Flowers CR, Nastoupil LJ, Nowakowski GS. The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell Lymphoma. American Society of Hematology (Blood) 142(Suppl 1), 2023. e-Pub 2023.
33. Westin J, Steiner RE, Chihara D, Ahmed S, Jain P, Malpica L, Iyer SP, Fayad L, Nair R, Nastoupil LJ, Neelapu SS, Henderson J, Rodriguez MA, Hagemeister FB, Vega F, Pulsifer B, Tom J, Durmic I, Masand G, Feng L, Green MR, Flowers CR, Strati S. Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma. American Society of Hematology (Blood) 142(Suppl 1), 2023. e-Pub 2023.
34. Maurer MJ, Khurana A, Mwangi R, Nowakowski GS, Casulo CA, Chihara D, Cohen JB, Kahl BS, Lossos IS, Martin P, Wang Y, McDonnell TJ, Feldman AL, Jaye DL, Habermann TM, Cerhan JR, Flowers CR, Link BK, Nastoupil LJ. Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma. American Society of Hematology (Blood) 142(Suppl 1), 2023. e-Pub 2023.
35. Lionel A, Long J, Prakash R, Edelkamp, Jr P, Knafl M, Ahmed S, Strati P, Nair R, Chien KS, Chihara D, Westin J, Khawaja F, Nastoupil LJ, J-G M, Mulanovich V, Team D, Daver N, Futreal A, Woodman SE, Flowers CR, Neelapu SS, Iyer SP. Differing Inflammatory Profiles and Survival Outcomes of Cytokine Storm Arising from CAR T-Cell Therapy, COVID and Malignancy-Associated HLH in Patients with Hematological Malignancies. American Society of Hematology (Blood) 142(Suppl 1), 2023. e-Pub 2023.
36. Day JR, Larson MC, Casulo C, Durani U, Wang Y, Chihara D, Nastoupil LJ, Kahl BS, Martin P, Lossos IS, Romancik JT, Ayers A, Burack R, Habermann TM, Cerhan JR, Flowers CR, Maurer MJ, Link BK. Patterns of Care and Prognostic Modeling Following Follicular Lymphoma Transformation to Aggressive B-Cell Lymphoma: An Analysis from the LEO Consortium. American Society of Hematology (Blood) 142(Suppl 1), 2023. e-Pub 2023.
37. Bommier C, Link BK, Gysbers B, Maurer MJ, Larson MC, Khurana A, Wang Y, Thompson C, Chihara D, Alderuccio JP, Koff JL, Lossos IS, Nowakowski GS, Feldman AL, Habermann TM, King RL, Cerhan JR. Cumulative Incidence, Predictors, and Outcomes of Transformation to Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Patients with Marginal Zone Lymphoma. American Socieyt of Hematology 142(Suppl 1), 2023. e-Pub 2023.
38. Chien, KS, Peterson CB, Young E, Chihara D, Manasanch EE, Ramdial JL, Thompson PA. Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies. Blood 140(Suppl 1), 2022. e-Pub 2022.
39. Ruan J, Larson MC, Chen Z, Bennani NN, Allen PB, Jaye DL, Cohen JB, Chihara D, Vega F, Inghirami G, Mou E, Casulo C, Mehta-Shah N, Martin P, Maurer MJ, Kahl BS, Lossos IS, Flowers CR, Cerhan JR, Feldman AL. Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study. Blood 140(Suppl 1):3666-3668, 2022. e-Pub 2022.
40. Strati P, Xubin Li X, Deng Q, Feng L, Sun R, Jallouk A, Adkins S, Cain T, Johncy S, Steiner RE, Ahmed S, Chihara D, Fayad L, Iyer SP, Horowitz SB, Nehlsen R, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Samaniego F, Rodriguez MA, Shpall EJ, Kebriaei P, Flowers CR, Hong D, Westin J, Neelapu SS, Green MR. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma. Blood 140(Suppl 1):7493-7495, 2022. e-Pub 2022.
41. Alderuccio JP, Reis IM, Koff JL, Larson MC, Chihara D, Zhao W, Haddadi S, Habermann TM, Martin P, Chapman-Fredricks JR, Strouse C, Kahl BS, Cohen JB, Friedberg JW, Cerhan JR, Flowers CR, Lossos IS. Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group. Blood 140(Suppl 1):9340-9341, 2022. e-Pub 2022.
42. Nair R, Ayers A, Nastoupil LJ, Gunther JR, Fayad L, Fowler NH, Miranda RN, Hagemeister FB, Lee HJ, Rodriguez MAR, Steiner R, Strati P, Nieto Y, Ramdial JL, Chihara D, Wang ML, Malpica Castillo LE, Saini N, Jain P, Pinnix CC, Dabaja BS, Green MR, Flowers CR, Medeiros LJ, Marques-Piubelli ML, Vega V, Noorani M, Ahmed S, Westin J, Neelapu SS, Feng L, Iyer SP. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL. Blood 140(Suppl 1):3800-3802, 2022. e-Pub 2022.
43. Nair R, Prakash R, Dang A, Gunther JR, Huen A, Xu J, Malpica Castillo LE, Torres Cabala C, Heberton M, Fang P, Ahmed S, Miranda RN, Fayad L, Steiner R, Lee HJ, Chihara D, Jain P, Srour SA, Ramdial JL, Nieto Y, Nastoupil LJ, Pinnix CC, Neelapu SS, Flowers CR, Medeiros LJ, Hosing H, Wang ML, Dabaja BS, Vega F, Feng L, Iyer SP. Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma. Blood 140(Suppl 1):12005-12007, 2022. e-Pub 2022.
44. Pinnix CC, Dabaja BS, Gunther JR, Fang F, Wu S, Ahmed S, Steiner RE, Nair R, Strati P, Westin J, Fayad L, Iyer SP, Rodriguez MA, Lee HJ, Samaniego F, Chihara, D Jain P, Feng L, Flowers CR, Neelapu SS, Nastoupil LJ. Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma. Blood 140(Suppl 1), 2022. e-Pub 2022.
45. Day JR, Larson MC, Casulo C, Wang Y, Chihara D, Kahl BS, Martin P, Lossos IS, Orellana-Noia VM, Burack R, Friedberg JW, Habermann TM, Cerhan JR, Flowers CR, Maurer MJ, Link BK. Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium. Blood 140(Suppl 1):6642-6644, 2022. e-Pub 2022.
46. Jallouk A, Feng L, Noorani M, Das K, Steiner RE, Nastoupil LJ, Hawkins M, Nair R, Westin W, Fayad L, Chihara D, Malpica Castillo LE, Iyer SP, Ahmed S, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy. Blood 140(Suppl 1):10424-10426, 2022. e-Pub 2022.
47. Chihara D, Liao L, Tkacz J, Lewing B, Franco A, Kilgore KM, Nastoupil LJ, Chen L. Real-World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in US. Blood 140(Suppl 1):2421-2423, 2022. e-Pub 2022.
48. Casulo C, Larson MC, Day JR, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Ruan J, Burack WR, Koff JL, Friedberg JW, Cerhan JR, Flowers C, Link BK, Maurer MJ. Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium. ASCO - JCO 40(16 Suppl), 2022. e-Pub 2022.
49. Marques-Piubelli ML, Solis LM, Malpica L, Gouni S, Nair R, Chihara D, Iyer SP, Wistuba II, Vega F, Strati P. Characterization of BCL-2 alternative proteins and outcome in patients with peripheral T-cell lymphoma (PTCL). ASCO - JCO 39(15 Suppl), 2021. e-Pub 2021.
50. Chihara D, Arons E, Stetler-Stevenson M, Yuan C, Zhou H, Raffeld M, Xi L, Steinberg SM, Wisch L, Feurtado J, James-Echenique L, Braylan R, Calvo KR, Maric I, Dulau A, Kreitman RJ. Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia. ASCO - JCO 37(15 Suppl), 2019. e-Pub 2019.
51. Ghorab A, Patel K, Cortes JE, Chihara D, Price A, Kadia TM, Ravandi F, Pemmaraju N, Daver NG, Dinardo CD, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden and mutation length on outcomes in acute myeloid leukemia with fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation. ASCO - JCO 36(15 Suppl), 2018. e-Pub 2018.
52. Sathyanarayanan V, Chihara D, Fanale MA, Costelloe CM, Ghonimi E, Shen C, Vega F, Dabaja BS, Oki Y, Zhou S, Hubert C. Prognostic value of PET-CT in early stage Hodgkin Lymphoma (HL) using updated 5 point scoring system. ASCO - JCO 34(15 Suppl), 2016. e-Pub 2016.
53. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros L, Fanale MA, Hagemeister FB, Fayad L, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL). ASCO - JCO 33(15 Suppl), 2015. e-Pub 2015.

Book Chapters

1. Chihara D, Oki Y. NK cell lymphomas. In: Systemic and Cutaneous T-cell Lymphoma, 2019.
2. Broccoli A, Chihara D, Fanale MA, Zinzani PL. Standard of Care in T-cell Lymphoma. In: Aggressive Lymphomas, 2018.
3. Chihara D, Wang C, Duvic M, Medeiros LJ, Oki Y. T-cell lymphoma. In: The MD Anderson Manual of Medical Oncology. Third Edition, 2016.
4. Chihara D, Hagemeister FB, Fanale MA. Hodgkin lymphomas. In: The MD Anderson Manual of Medical Oncology. Third Edition, 2016.

Letters to the Editor

1. Chihara D, Gras L, Zinger N, Kroger N, Mayer J, Passweg J, De Latour RP, Byrne J, Kruger W, Bohn JP, Platzbecker U, Blau IW, Bonifazi F, Helbig G, McDonald A, Mistrik M, Mohty M, Ram R, Sanz J, Llamas CV, Kreitman RJ, Hayden PJ, McLornan D, Tournilhac O, Van Gelder M, Yakoub-Agha I. Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience. Haematologica 108: 1676-1679, 2023.
2. Marques-Piubelli ML, Solis LM, Parra ER, Castillo LM, Gouni S, Nair R, Chihara D, Konopleva M, Wistuba II, Iyer SP, Vega F, Strati P. BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified. Blood Cancer J 11: 153, 2021.
3. Kondo E, Shimizu-Koresawa R, Chihara D, Mizuta S, Izutsu K, Ikegame K, Uchida N, Fukuda T, Ichinohe T, Atsuta Y, Suzuki R. Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantation registry. Br J Haematol 186: e219-e223, 2019.
4. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica 103: e416-e418, 2018.
5. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol 179: 851-854, 2017.
6. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol 179: 503-506, 2017.
7. Kato H, Yamamoto K, Oki Y, Ine S, Taji H, Chihara D, Kagami Y, Seto M, Morishima Y. Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas. Leukemia 26: 166-9, 2012.
8. Chihara D, Suzuki R. More on crizotinib. N Engl J Med 364: 776-7; author reply 778, 2011.